Updated Nov. 17, 2023 12:29 pm ET
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
0846 ET – Twist Bioscience is feeling optimistic about the year ahead after orders picked up and revenue exceeded analyst expectations in its F4Q, which ended Sept. 30. The San Francisco-based biotech company is expecting momentum behind its SynBio product group to be bolstered by Express Genes, its new gene synthesis service, and for its next-generation sequencing business to grow as customers advance their development and commercial plans, CEO Emily Leproust says. Twist is guiding for annual revenue to rise 16% to 18%, with that same growth rate for its SynBio unit. Twist expects 19% to 20% revenue growth for its next-generation sequencing business and a smaller 8% uptick in its Biopharma Solutions segment. Shares gain 6.7% to $20.35 premarket. (dean.seal@wsj.com)
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8